文献速递心力衰竭与心肌病

SGLT2抑制剂联合盐皮质激素受体拮抗剂在心衰中的荟萃分析

Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
PubMed 文献 · Eur Heart J · 2023-01-01

该荟萃分析纳入5项随机对照研究、21 947例心衰患者,评估SGLT2抑制剂(SGLT2i)与盐皮质激素受体拮抗剂(MRA)联用的心血管效应。结果显示,无论是否使用MRA,SGLT2i对心衰住院/心血管死亡复合终点、心衰住院和全因死亡的影响相似;在慢性心衰患者中,使用MRA者随机接受SGLT2i的心血管死亡相对降幅更明显。SGLT2i可减轻MRA相关的治疗中出现的高钾血症风险。

核心结论

  • MRA不影响SGLT2i对心衰住院/心血管死亡复合终点、心衰住院或全因死亡的作用。
  • 在慢性心衰患者中,使用MRA者随机接受SGLT2i的心血管死亡相对降幅更明显,提示更显著的相对降低。
  • SGLT2i可减轻MRA相关的治疗中出现的高钾血症风险。

研究设计与样本

  • 检索PubMed/MEDLINE、Web of Science、Embase和临床试验注册库,纳入评估SGLT2i用于心衰伴或不伴MRA使用的随机对照试验/事后分析(PROSPERO: CRD42023397129)。
  • 共纳入5项研究,汇总21 947例心衰患者数据(其中2型糖尿病10 805例)。
  • 采用固定效应荟萃分析和亚组分析,提取风险比(HR)/风险比(RR)。

临床怎么用

  • 心衰患者使用MRA时,联合SGLT2i可维持其对心衰住院/心血管死亡复合终点的获益。
  • 对于使用MRA的慢性心衰患者,SGLT2i可能带来更明显的心血管死亡相对降幅。
  • SGLT2i有助于降低MRA相关的治疗中出现的高钾血症风险。

局限性

  • 研究结果需在精心设计的随机对照试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: To investigate the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist (MRA) use in heart failure (HF) regardless of ejection fraction (EF) and explore the risk of MRA-associated adverse events in individuals randomized to SGLT2i vs. placebo. METHODS: PubMed/MEDLINE, Web of Science, Embase, and clinical trial registries were searched for randomized controlled trials/post-hoc analyses evaluating SGLT2i in HF with or without MRA use (PROSPERO: CRD42023397129). The main outcomes were composite of first hospitalization or urgent visit for HF/cardiovascular death (HHF/CVD), HHF, and CVD. Others were all-cause mortality, composite renal and safety outcomes. Hazard ratios (HR)/risk ratios were extracted. Fixed-effects meta-analyses and subgroup analyses were performed. RESULTS: Five eligible studies were included, pooling data from 21 947 people with HF (type 2 diabetes mellitus, n = 10 805). Compared to placebo, randomization to SGLT2i showed a similar reduction in HHF/CVD and HHF in people who were or were not using MRAs [HHF/CVD: hazard ratio (HR) 0.75; 95% confidence interval (CI) 0.68-0.81 vs. HR 0.79; 95% CI 0.72-0.86; P-interaction = .43; HHF: HR 0.74; 95% CI 0.67-0.83 vs. HR 0.71; 95% CI 0.63-0.80; P-interaction = .53], with a suggestion of greater relative reduction in CVD in chronic HF people randomized to SGLT2i and using MRAs irrespective of EF (HR 0.81; 95% CI 0.72-0.91 vs. HR 0.98; 95% CI 0.86-1.13; P-interaction = .034). SGLT2i reduced all-cause mortality (P-interaction = .27) and adverse renal endpoints regardless of MRA use (P-interaction = .73) despite a higher risk of volume depletion with concomitant MRAs (P-interaction = .082). SGLT2i attenuated the risk of mild hyperkalaemia (P-interaction < .001) and severe hyperkalaemia (P-interaction = .051) associated with MRA use. CONCLUSIONS: MRAs did not influence SGLT2i effects on the composite of HHF/CVD, HHF or all-cause mortality; however, findings hinted at a more pronounced relative reduction in CVD in chronic HF patients regardless of EF who were randomized to SGLT2i and receiving an MRA compared to those randomized to SGLT2i and not receiving MRAs. SGLT2i attenuated the risk of MRA-associated treatment-emergent hyperkalaemia. These findings warrant further validation in well-designed randomized controlled trials.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Banerjee, Maisnam, Pal, et al. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis. Eur Heart J. 2023. PMID: 37605637. doi:10.1093/eurheartj/ehad522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。